Alain Munoz
Président chez ACTICOR BIOTECH SAS
Fortune : 1 M $ au 31/05/2024
Provenance du réseau au premier degré de Alain Munoz
| Entité | Type d'entité | Industrie | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 61 | |
| Public Company | Biotechnology | 20 | |
Novagali Pharma SA
 Novagali Pharma SA Pharmaceuticals: MajorHealth Technology Novagali Pharma SA specializes in research, development and marketing of ophthalmic drugs. Their product pipeline includes products at various stages of development, which address diseases encountered at the three different segment levels of the eye which are surface, anterior and posterior segments. Some of these diseases are dry eye, allergy, glaucoma and retinopathies. Their formulations are based on their technology platforms Novasorb and Eyeject, which optimize bioavailability of drugs as well as safety and comfort for the patient. The company was founded on August 8, 2000 and is headquartered in Evry, France.
16
| Extinct | Pharmaceuticals: Major | 16 |
| Subsidiary | Pharmaceuticals: Major | 15 | |
12
| Public Company | Pharmaceuticals: Major | 12 |
Vivalis SA
 Vivalis SA Pharmaceuticals: OtherHealth Technology Vivalis SA manufactures human and animal vaccines. The firm specializes in the research and development of vaccines and antiviral molecules, as well as in recombinant therapeutic protein and monoclonal antibody expression systems development. The firm's embryonic stem cells are used for practical applications in human and animal health. It also helps its clients in a case by case basis for the development of processes in the frame of service agreement. The company was founded in April 1999 and is headquartered in France.
11
| Extinct | Pharmaceuticals: Other | 11 |
| Public Company | Biotechnology | 11 | |
Genticel SA
 Genticel SA BiotechnologyHealth Technology Genticel SA operates as a clinical stage biotechnology company, which focuses on the development of immunotherapies designed to fight infectious diseases and cancer. The company was founded by Bénédikt Timmerman and Ludovic de Meeus d'Argenteuil on October 15, 2001 and is headquartered in Labège, France.
9
| Extinct | Biotechnology | 9 |
Auris Medical Holding AG /Old/
 Auris Medical Holding AG /Old/ Medical SpecialtiesHealth Technology Auris Medical Holding AG engages in the research, development, and commercialization of pharmaceutical products for inner ear disorders. Its products portfolio targets to treat tinnitus, Menière's disease, and hearing loss. The company was founded by Thomas Meyer on April 1, 1998 and is headquartered in Zug, Switzerland.
8
| Extinct | Medical Specialties | 8 |
Auris Medical AG
 Auris Medical AG Medical SpecialtiesHealth Technology Auris Medical AG manufactures electronic devices for ear disorders. It develops novel pharmaceutical therapies to protect hearing and to silence tinnitus. The company was founded by Thomas Meyer in April 2003 and is headquartered in Basel, Switzerland.
4
| Subsidiary | Medical Specialties | 4 |
Intercell Austria AG
3
| Private Company | 3 | |
Fournier Group, Inc.
 Fournier Group, Inc. Multi-Line InsuranceFinance Part of RSC Insurance Brokerage, Inc., Fournier Group, Inc. is a dynamic independent insurance agency headquartered in Portland, OR. Fournier Group, Inc. provides personal (home/auto/specialty), business, and aviation insurance to diverse clients. The company was founded by Dirk Fournier. Fournier Group was acquired by RSC Insurance Brokerage, Inc. on December 09, 2021.
1
| Subsidiary | Multi-Line Insurance | 1 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Alain Munoz via son réseau personnel
| Société | Secteur | Personnes liées | Poste principal |
|---|---|---|---|
Amryt Pharma Holdings Ltd.
 Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Chairman Director/Board Member Founder Director/Board Member Compliance Officer Director/Board Member Director/Board Member Director/Board Member Director/Board Member General Counsel Public Communications Contact Human Resources Officer Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
| University of Copenhagen | College/University | Doctorate Degree Undergraduate Degree Corporate Officer/Principal Doctorate Degree Doctorate Degree Doctorate Degree Doctorate Degree Graduate Degree | |
| VALNEVA | Biotechnology | Corporate Officer/Principal Chairman Corporate Officer/Principal Chief Tech/Sci/R&D Officer Chief Executive Officer | |
| GAMIDA CELL LTD. | Pharmaceuticals: Major | Director/Board Member Chief Operating Officer Chief Executive Officer Corporate Officer/Principal | |
| NOVO NORDISK A/S | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| AEGERION PHARMACEUTICALS, INC. | Pharmaceuticals: Major | President Director/Board Member Director/Board Member Corporate Officer/Principal | |
| VALERIO THERAPEUTICS | Pharmaceuticals: Major | Founder Director/Board Member Director/Board Member Investor Relations Contact | |
| H. LUNDBECK A/S | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal Public Communications Contact Director/Board Member | |
| Copenhagen Business School | College/University | Graduate Degree Graduate Degree Graduate Degree | |
| INSEAD | College/University | Masters Business Admin Masters Business Admin Masters Business Admin | |
| VOLUNTIS S.A. | Packaged Software | Director/Board Member Director/Board Member Director/Board Member | |
| University of Lund | College/University | Graduate Degree Undergraduate Degree Undergraduate Degree | |
| Harvard Business School | College/University | Masters Business Admin Graduate Degree Masters Business Admin | |
| University of Aarhus | College/University | Corporate Officer/Principal Masters Business Admin Undergraduate Degree | |
| PHAXIAM THERAPEUTICS S.A. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Chairman Director/Board Member | |
Minka Therapeutics SA
 Minka Therapeutics SA Pharmaceuticals: MajorHealth Technology Minka Therapeutics SA develops therapeutic products and diagnostic complementary to current antiretroviral therapy in the treatment of AIDS. The firm provides therapeutic and diagnostic solutions for diseases linked to the immune system through its research on immune dysregulations. The company was founded by Patrice Debre, Vincent Vieillard, Michel Klein, Joël Crouzet, and Robert L. Murphy in 2008 and is headquartered in Evry, France. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Chief Tech/Sci/R&D Officer | |
Kymab Ltd.
 Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Major | Chairman Director/Board Member Founder | |
| BIOINVENT INTERNATIONAL AB | Biotechnology | Chairman Director/Board Member | |
Eyevensys SAS
 Eyevensys SAS Miscellaneous Commercial ServicesCommercial Services Eyevensys SAS develops non-viral gene therapy process for the treatment of ocular illnesses. The firm's process enables prolonged production of all therapeutic proteins through electrotransfer. Its product, the single-used device is designed for treating ocular illnesses. The company was founded by Francine Behar-Cohen on December 8, 2008 and is headquartered in Paris, France. | Miscellaneous Commercial Services | Director/Board Member Chief Executive Officer | |
| SANOFI | Biotechnology | Corporate Officer/Principal Corporate Officer/Principal | |
| Danmarks Farmaceutiske Universitet | College/University | Graduate Degree Undergraduate Degree | |
| NOVARTIS AG | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| TDC A/S | Major Telecommunications | Corporate Officer/Principal Corporate Officer/Principal | |
| TXCELL | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
| BIOPORTO A/S | Medical Specialties | Director/Board Member Director/Board Member | |
| Technical University of Denmark | College/University | Graduate Degree Graduate Degree | |
Dansk Biotek
 Dansk Biotek Miscellaneous Commercial ServicesCommercial Services Dansk Biotek is an industry association for biotech companies with promoting the biotechnological research, development and production in taking care of corporate interests in this regard, both nationally and internationally. The company was founded in 1987 and is headquartered in Copenhagen, Denmark. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
| AVT Business School A/S | College/University | Chairman Masters Business Admin | |
ProFibrix BV
 ProFibrix BV BiotechnologyHealth Technology ProFibrix BV develops and markets products for the hemostasis and regenerative medicine markets. Its product in pipeline, ProFibrix, is a hemostatic agent for mild to moderate surgical bleeding. The firm operates through its offices located in Leiden and Seattle. It is a subsidiary of The Medicines Company. The company was founded in 2004 by Jaap Koopman and is headquartered in Leiden, the Netherlands. | Biotechnology | Chairman Director/Board Member | |
| ESSEC Business School | College/University | Graduate Degree Masters Business Admin | |
| Roche SAS | President Corporate Officer/Principal | ||
| Weill Cornell Medical College | College/University | Corporate Officer/Principal Doctorate Degree | |
| ALLIGATOR BIOSCIENCE AB | Biotechnology | Chairman Director/Board Member | |
| AMGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
| Columbia University College of Physicians & Surgeons | College/University | Doctorate Degree Corporate Officer/Principal | |
| University of Strasbourg | College/University | Doctorate Degree Doctorate Degree | |
| BASILEA PHARMACEUTICA AG | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
American Bar Association
 American Bar Association Miscellaneous Commercial ServicesCommercial Services American Bar Association provides legal services. It provides law school accreditation, continuing legal education, legal information and other services to assist legal professionals. The firm has members which include judges, court administrators, law professors, and non-practicing attorneys. The company was founded on August 21, 1878 and is headquartered in Chicago, IL. | Miscellaneous Commercial Services | Chairman Corporate Officer/Principal | |
| Université Libre de Bruxelles | College/University | Undergraduate Degree Graduate Degree | |
| CHIASMA, INC. | Pharmaceuticals: Major | Chief Executive Officer Chief Executive Officer | |
MedDay Pharmaceuticals SAS
 MedDay Pharmaceuticals SAS BiotechnologyHealth Technology MedDay Pharmaceuticals SAS operates as a biotechnology company developing new drugs for nervous system disorders. The firm operates for the treatment of neuro-metabolic diseases. The company was founded by Frédéric Sedel and Guillaume Brion in 2011 and is headquartered in Paris, France. | Biotechnology | Director/Board Member Chief Executive Officer | |
| École des Hautes Études Commerciales de Paris | College/University | Masters Business Admin Masters Business Admin | |
| TEVA PHARMACEUTICAL INDUSTRIES LIMITED | Pharmaceuticals: Generic | Director/Board Member Director of Finance/CFO | |
CYTOO SA
 CYTOO SA Medical SpecialtiesHealth Technology CYTOO SA operates as a contract research organization which develops physiological cell-based assays. It focuses on developing, manufacturing, and commercializing new technologies for cell analysis for life sciences research community. The company has offices in Bethesda and Grenoble. The company was founded by François Chatelain, Alexandra Fuchs and Jacques Lewiner in 2008 and is headquartered in Grenoble, France. | Medical Specialties | Chief Executive Officer Director/Board Member | |
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal |
Statistiques
Internationale
| France | 19 |
| Danemark | 12 |
| Etats-Unis | 10 |
| Suède | 4 |
| Royaume-Uni | 3 |
Sectorielle
| Health Technology | 29 |
| Consumer Services | 16 |
| Commercial Services | 5 |
| Technology Services | 2 |
| Communications | 2 |
Opérationnelle
| Director/Board Member | 572 |
| Corporate Officer/Principal | 205 |
| Chairman | 154 |
| Independent Dir/Board Member | 142 |
| Chief Executive Officer | 106 |
Relations les plus connectées
| Insiders | |
|---|---|
| Peter James Arthur Benson | 58 |
| Antoine Papiernik | 48 |
| Philippe Peltier | 45 |
| Frédéric Grimaud | 33 |
| Alf Gunnar Martin Nicklasson | 31 |
| Patrick Volkert Vink | 30 |
| Alain Parthoens | 29 |
| Catherine Moukheibir | 29 |
| Gerald Heinz Möller | 29 |
| Rémi Droller | 29 |
| Jeffrey Berkowitz | 26 |
| Didier Hoch | 24 |
| Rosemary Crane | 23 |
| Berndt A. E. Modig | 23 |
| Leonard Kruimer | 22 |
- Bourse
- Insiders
- Alain Munoz
- Connexions Sociétés
